Vijay Kumar
Stock Analyst at Evercore ISI Group
(2.36)
# 2,602
Out of 4,966 analysts
235
Total ratings
46.67%
Success rate
-3.07%
Average return
Main Sectors:
Stocks Rated by Vijay Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: In-Line | $130 → $128 | $125.66 | +1.86% | 6 | Aug 28, 2025 | |
| CAI Caris Life Sciences | Maintains: Outperform | $33 → $40 | $38.39 | +4.19% | 2 | Aug 13, 2025 | |
| EXAS Exact Sciences | Maintains: Outperform | $68 → $64 | $47.42 | +34.96% | 6 | Aug 8, 2025 | |
| AZTA Azenta | Maintains: In-Line | $35 → $33 | $30.54 | +8.06% | 8 | Aug 5, 2025 | |
| MTD Mettler-Toledo International | Maintains: Outperform | $1,280 → $1,275 | $1,301.04 | -2.00% | 11 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Outperform | $18 → $16 | $13.47 | +18.78% | 11 | Aug 4, 2025 | |
| EW Edwards Lifesciences | Maintains: In-Line | $77 → $80 | $81.34 | -1.65% | 13 | Jul 25, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: In-Line | $102 → $96 | $106.10 | -9.52% | 13 | Jul 8, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $500 → $480 | $492.72 | -2.58% | 12 | Jul 8, 2025 | |
| SYK Stryker | Maintains: Outperform | $390 → $415 | $391.41 | +6.03% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $116 → $115 | $90.11 | +27.62% | 2 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $103 → $106 | $92.81 | +14.21% | 5 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $470 → $550 | $473.30 | +16.21% | 13 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $116 → $128 | $99.96 | +28.05% | 7 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $62 → $68 | $67.12 | +1.31% | 15 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $46 | $30.90 | +48.87% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $226 | $205.82 | +9.80% | 3 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $16 | $14.63 | +9.36% | 9 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $42 | $24.69 | +70.11% | 7 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $132.66 | +9.30% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $44 → $49 | $48.83 | +0.35% | 6 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $3 | $3.31 | -9.37% | 6 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $96 → $85 | $73.73 | +15.29% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $112 | $105.50 | +6.16% | 6 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $207 → $202 | $144.99 | +39.32% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $18 → $30 | $12.33 | +143.31% | 11 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $335 → $355 | $301.80 | +17.63% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $56 | $26.97 | +107.64% | 5 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $160 | $67.64 | +136.55% | 7 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $286 → $290 | $192.98 | +50.27% | 6 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.24 | +464.52% | 1 | May 31, 2022 |
Agilent Technologies
Aug 28, 2025
Maintains: In-Line
Price Target: $130 → $128
Current: $125.66
Upside: +1.86%
Caris Life Sciences
Aug 13, 2025
Maintains: Outperform
Price Target: $33 → $40
Current: $38.39
Upside: +4.19%
Exact Sciences
Aug 8, 2025
Maintains: Outperform
Price Target: $68 → $64
Current: $47.42
Upside: +34.96%
Azenta
Aug 5, 2025
Maintains: In-Line
Price Target: $35 → $33
Current: $30.54
Upside: +8.06%
Mettler-Toledo International
Aug 4, 2025
Maintains: Outperform
Price Target: $1,280 → $1,275
Current: $1,301.04
Upside: -2.00%
Avantor
Aug 4, 2025
Maintains: Outperform
Price Target: $18 → $16
Current: $13.47
Upside: +18.78%
Edwards Lifesciences
Jul 25, 2025
Maintains: In-Line
Price Target: $77 → $80
Current: $81.34
Upside: -1.65%
Zimmer Biomet Holdings
Jul 8, 2025
Maintains: In-Line
Price Target: $102 → $96
Current: $106.10
Upside: -9.52%
Thermo Fisher Scientific
Jul 8, 2025
Maintains: Outperform
Price Target: $500 → $480
Current: $492.72
Upside: -2.58%
Stryker
Jul 8, 2025
Maintains: Outperform
Price Target: $390 → $415
Current: $391.41
Upside: +6.03%
Jul 8, 2025
Maintains: Outperform
Price Target: $116 → $115
Current: $90.11
Upside: +27.62%
Jul 8, 2025
Maintains: Outperform
Price Target: $103 → $106
Current: $92.81
Upside: +14.21%
Jul 8, 2025
Maintains: In-Line
Price Target: $470 → $550
Current: $473.30
Upside: +16.21%
Jul 8, 2025
Maintains: Outperform
Price Target: $116 → $128
Current: $99.96
Upside: +28.05%
Jul 8, 2025
Maintains: In-Line
Price Target: $62 → $68
Current: $67.12
Upside: +1.31%
Jul 8, 2025
Maintains: Outperform
Price Target: $48 → $46
Current: $30.90
Upside: +48.87%
Jul 8, 2025
Maintains: Outperform
Price Target: $230 → $226
Current: $205.82
Upside: +9.80%
Jul 8, 2025
Maintains: Outperform
Price Target: $16 → $16
Current: $14.63
Upside: +9.36%
Jul 8, 2025
Maintains: Outperform
Price Target: $44 → $42
Current: $24.69
Upside: +70.11%
Jul 8, 2025
Maintains: Outperform
Price Target: $140 → $145
Current: $132.66
Upside: +9.30%
Jun 4, 2025
Maintains: In-Line
Price Target: $44 → $49
Current: $48.83
Upside: +0.35%
May 19, 2025
Maintains: In-Line
Price Target: $3
Current: $3.31
Upside: -9.37%
May 1, 2025
Maintains: Outperform
Price Target: $96 → $85
Current: $73.73
Upside: +15.29%
Apr 24, 2025
Maintains: Outperform
Price Target: $110 → $112
Current: $105.50
Upside: +6.16%
Jan 17, 2025
Maintains: Outperform
Price Target: $207 → $202
Current: $144.99
Upside: +39.32%
Dec 2, 2024
Upgrades: Outperform
Price Target: $18 → $30
Current: $12.33
Upside: +143.31%
Oct 1, 2024
Maintains: In-Line
Price Target: $335 → $355
Current: $301.80
Upside: +17.63%
Oct 1, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $26.97
Upside: +107.64%
Oct 1, 2024
Maintains: Outperform
Price Target: $120 → $160
Current: $67.64
Upside: +136.55%
Oct 1, 2024
Maintains: Outperform
Price Target: $286 → $290
Current: $192.98
Upside: +50.27%
May 31, 2022
Initiates: Outperform
Price Target: $7
Current: $1.24
Upside: +464.52%